Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia

NCT01968980 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01968980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01968980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 23, 2013
Completion date
April 15, 2016
Enrollment
370 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia